Antineoplastics Reactions 1680, p40 - 2 Dec 2017 Epstein-Barr virus related primary diffuse large B- cell lymphoma of the central nervous system: case report A 66-year-old man developed Epstein-Barr virus (EBV) related primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL) after chemotherapy with doxorubicin, vincristine, cyclophosphamide, prednisone, etoposide, cytarabine and dexamethasone [time to reaction onsets and routes not stated; not all outcomes stated]. The man was diagnosed with CCR4-positive peripheral T- cell lymphoma, not otherwise specified (PTCL-NOS). He received CHOP chemotherapy including doxorubicin 2 2 50 mg/m , vincristine 1.4 mg/m and cyclophosphamide 2 2 750 mg/m on day 1; prednisone 60 mg/m on days 1-5 and CHASE chemotherapy including etoposide 100 mg/m on days 1-3; cyclophosphamide 1,200 mg/m on day 1; cytarabine 1,000 mg/m on days 2 and 3 and dexamethasone 40 mg/body on days 1-3. Since the CHOP and CHASE chemotherapies were ineffective, he then received mogamulizumab therapy each week. After 7 cycles of the mogamulizumab therapy, he developed paralysis of right upper limb. Brain MRI revealed multiple brain tumors with ring enhancement. CSF examination showed EBV-DNA without abnormal cells. A brain biopsy showed bleeding, oedema and destruction as well as infiltration by abnormal small circular cells around the blood vessels of the brain parenchyma. These abnormal cells expressed L26, but not CD3 and CD5; however, PTCL cells were positive for CD3 and CD5 before the chemotherapies. In situ hybridisation of these cells revealed positivity for EBV-encoded small RNA. Based on these findings, a diagnosis of EBV-related CNS DLBCL as a secondary malignancy was made. A review of previously performed axial lymph node biopsy showed EBV-encoded small RNA positivity for CD20-positive B-lymphocytes around the PTCL cells. The man received palliative treatment. Eventually, 4 months after the diagnosis of PTCL-NOS, he died while comatose [cause of death not stated]. Author comment: "We cannot exclude the possibility that severe immunosuppression due to [peripheral T-cell lymphoma, not otherwise specified] itself and the previous chemotherapies already existed before mogamulizumab treatment and resulted in the development of the [Epstein- Barr virus (EBV) related primary diffuse large B-cell lymphoma of the central nervous system]." Tanaka H, et al. Development of epstein-barr virus-related primary diffuse large B- cell lymphoma of the central nervous system in a patient with peripheral T-cell lymphoma, not otherwise specified after mogamulizumab treatment. Internal Medicine 56: 2759-2763, No. 20, Jan 2017. Available from: URL: http:// - Japan 803284153 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial